Eugenio Aringhieri

MacroChem Corp. Develops pharmaceutical products to prevent chemicals in insect repellant from penetrating the skin. Its drug delivery technologies include Soft Enhancement of Percutaneous Absorption, MacroDem and DermaPass. The company was founded in 1982 and is located in Wellesley Hills, MI.

BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA.

SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA.

Les Laboratoires Servier SAS manufactures medicines for the treatment of diabetes, venous disease, and cancer. It also offers pharmaceutical products for cardiovascular illnesses such as hypertension, heart failure, and stroke. The company was founded by Jacques Servier in 1954 and is headquartered in Suresnes, France.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY.

The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX.

Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.

Avon Foundation For Women provides granting services. The non-profit company is based in New York, NY.

EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark.

Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA.

Cancer Prevention & Research Institute of Texas provides cancer research and prevention programs and services. It is the state agency mandated to create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of cancer and cures for cancer. The company was founded in 2007 and is headquartered in Austin, TX.

Institut Gustave Roussy EURL is a cancer research and treatment center that places innovation at the heart of its services. The private company is based in Chevilly-Larue, France, and has subsidiaries in France. The center has strong partnerships at national and international levels to provide high-value care to all its patients. Patients' rights are protected and guaranteed to ensure their autonomy, respect for their individual liberties, and dignity within the hospital.

Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded on May 28, 1997 and is headquartered in Pleasanton, CA.

Highgate LLC is a hospitality management and investing private company based in Birmingham, MI. Highgate LLC delivers market intelligence, scale, and technology to the hospitality industry. Highgate is known for its expertise in hotel management, investment, technology, and development, and has a diverse portfolio of hotels. The company was founded by Yvonne L. Greenstreet and Stephen R. Polk has been the CEO since 2013.

Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom.

Part of MEDIAN Technologies SA, Median Technologies, Inc. provides medical imaging services. The company is based in Burlington, MA. The CEO of the company is Fredrik Bjjorn Brag.

Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The company is based in Abingdon, UK and was founded in 2015.

Mariana Oncology, Inc., also known as Curie Therapeutics, is a radiopharmaceuticals company that specializes in developing safe and effective targeted radiopharmaceuticals for cancer treatment. The company is based in Woburn, MA and was founded by Simon Read, who has been the CEO since incorporation. The company's radiopharmaceuticals are designed to deliver alpha and beta-emitting radionuclide payloads to carefully selected biological targets.

Newcleo Ltd. is a British company that is disrupting the nuclear energy industry to play its part in climate change mitigation and decarbonization. Newcleo is based in an undisclosed location. The company is focused on reducing the environmental impact of nuclear fission and providing safe and clean energy to meet the growing energy needs. Newcleo has announced an agreement to purchase the outstanding shares of the Rütschi Group for a consideration of EUR 68.9 million. The company is planning ahead to work together with potential local, regional, and international suppliers to maximize the opportunities that Newcleo can bring. The company was founded in 2021 by Elisabeth Rizzotti and Stefano Buono, who has been the CEO since 2021.

Kirilys Therapeutics, Inc. is an American preclinical-stage biopharmaceutical company that focuses on developing multiple precision oncology assets. The company is based in California and is committed to advancing the field of oncology. The company's initial asset is KRLS-017, a novel CDK7 inhibitor that has the potential to improve the treatment of multiple cancers. Kirilys Therapeutics was founded by Takeshi Takahashi, Brian Taylor Slingsby, and Kapil Dhingra, with Brian Taylor Slingsby serving as the CEO since incorporation.